Non-small cell lung cancer
Conditions
Interventions
MET exon 14 skipping mutations:Observational study, not applicable
MET gene amplification:Observational study, not applicable
MET protein overexpression:Observational study, not applicable
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Patient was aged = 18 years; 2) Patients were histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage III-IV) and were not suitable to receive radical resection or chemoradiotherapy; 3) Patient had MET alteration(METex14 skipping, MET gene amplification and MET protein overexpression); 4) Patients who had started glumetinib treatment before before entering this trial; 5) Subjects fully understand and volunteered to participate in this study and had good compliance to follow-up
Exclusion criteria
Exclusion criteria: 1) Known intolerance or allergy to study drug; 2) Involved in other interventional clinical trials at the same time; 3) Patients were undergoing anti-cancer treatment with unmarketed drugs in China; 4) Combined with other malignant tumors and required to treatment; 5) Unsuitable subjects for this study determined by the investigator 6) pregnant or breast-feeding patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to treatment discontinuation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;Real world response rate;Real world disease control rate;Real world progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactJun Zhao
Beijing Cancer Hospital
Outcome results
None listed